•  
  •  
 

Corresponding Author

Sahar Hassan Abd Allah

Document Type

Original Article

Abstract

Background: The sever acute respiratory syndrome corona virus-2 (SARS_CoV-2) is a novel Corona virus that causes Corona virus disease 2019 (COVID- 19). Except for respiratory symptoms, COVID-19 patient often develop different degrees of liver injury. Notably, COVID-19 patients with pre-existing liver diseases, especially liver cirrhosis, have higher incidence of liver biochemical abnormality, liver injury, and even hepatic decompensation event. Aim: To determine the liver biochemistry changes in COVID-19 patients. Patients and methods: In this retrospective study was conducted in quarantine department, Assuit Chest Hospital was conducted on 761 COVID-19 patients. Patients were divided into 2 groups: hepatic and non-hepatic groups. Results: Hepatic patients showed significant elevation in AST and ALT compared to non hepatic patients. There was statistically significant difference between COVID-19 patients with normal and altered liver function regarding treat�ment. Patients with altered liver function tests showed significant elevation in INR compared to patients with normal liver function tests. There was no statistically significant difference between COVID-19 patients with normal and altered liver function regarding mortality. There was no statistically significant difference between them regarding pH, PCO2, HCO3, SO2, Na and K. Conclusion: Liver biochemical abnormality is more common in COVID-19 patients with liver cirrhosis. However, liver cirrhosis patients without COVID-19 have more hepatic decompensation events, so they should not be delayed from their hospitalization management during the COVID-19 pandemic. The presence of abnormal liver tests on admission was not associated with COVID-19 severity and mortality

Keywords

COVID-19, Liver, SARS-COV-2

Subject Area

Internal Medicine

Download

Share

COinS